Expresses Cas9-Nlux and sgRNA and contains CEN/ARS. CCMP537 LDSP promoter driven Blasticidin resistance gene.

Sequence specific sgRNA that guide Cas9 to the genomic region encoding the bovine Creb5 DNA binding domain

Lentiviral CRISPR-Cas9 plasmid containing gRNA targeting exon 1 of human Tollip. Used for generation of Tollip protein knockouts in human cell lines.

Lentiviral expression of Cas9 and gRNA targeting PBRM1

Lentiviral expression of Cas9 and gRNA targeting PBRM1

CRISPR-dCas9-VPR vector for Yarrowia lipolytica, expressing dCas9-VPR and AvrII site for sgRNA insertion

3rd generation lentiviral vector expressing GFP alongside Cas9 and an sgRNA cloning site

Introduce sgRNA into a lentiviral vector (LentiCRISPR V2) which contains eSpCas9 and puromycin cassette

CRISPR-dCas9-Mxi1 vector for Yarrowia lipolytica, expressing dCas9-Mxi1 and AvrII site for sgRNA insertion

CRISPR knockout, expresses Cas9, and sgRNA targeting Human SORCS2

Lentiviral vector expressing Cre recombinase alongside Cas9 and an sgRNA cloning site

Lentiviral transfer plasmid to express Cas9 and a gRNA targeting the human CD20 gene, MS4A1.

Derivative of MG1655 used for the screening of clones able to survive the bad seed toxicity of dCas9, while still efficiently silencing the expression of mcherry

Knockout eGFP

Knockout eGFP

Knockout eGFP

Knockout eGFP

Expresses CRISPRoff-v2.1 (DNMT3A-DNMT3L-XTEN80-dCas9-HA-2xNLS-BFP-KRAB) downstream of the CAG promoter

Bassik lab Human CRISPR-Cas9 Deletion Library - Gene Expression. Coexpresses mCherry.

Ready-to-use AAV Retrograde particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.